telaprevir

12/01/2014 - "Telaprevir (TVR)-based triple therapy has substantially improved cure rates of hepatitis C virus (HCV) genotype 1 infection but side effects are frequent and often severe. "
01/01/2014 - "Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection."
01/01/2015 - "Aim of the present study was to analyse telaprevir plasma concentrations in patients with HCV genotype 1 infection after OLT in comparison to patients without OLT and IS. "
06/01/2013 - "Study C209 evaluated the activity of telaprevir in treatment-naïve patients with genotypes 2 or 3 (G2, G3) hepatitis C virus (HCV) infection. "
08/01/2005 - "In November 2004, Vertex initiated a phase Ib European trial of VX-950 for the treatment of HCV infection."

01/01/2014 - "Telaprevir-based triple therapy is a highly effective treatment for chronic hepatitis C. "
08/01/2013 - "Telaprevir-based triple therapy is highly effective for chronic hepatitis C. "
12/01/2014 - "This study investigated the relationship between hepatitis C virus (HCV) dynamics and sustained virological response (SVR), as well as the efficacy of an extended treatment with telaprevir-based triple therapy among patients with chronic hepatitis C genotype 1b. "
07/01/2015 - "Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan."
01/01/2015 - "Safety and efficacy of partial splenic embolization in telaprevir-based triple therapy for chronic hepatitis C."

12/01/2014 - "A significantly greater proportion of patients were persistent to the 3-drug hepatitis C regimen containing telaprevir in specialty pharmacy, compared with retail pharmacy (56.0% vs. 39.9%, P  less than  0.001). "
11/18/2015 - "To investigate the efficacy of virological response (VR) to telaprevir (TVR)-based triple therapy in predicting treatment outcome of hepatitis C. "
04/01/2015 - "Hepatitis C genotype 1b and 4 cured after telaprevir-based therapy."
01/01/2013 - "This article briefly reviews the properties of telaprevir and its status in the context of rapidly evolving aspects of management of chronic hepatitis C."
12/01/2014 - "Continuously eligible patients who started a new 3-drug regimen containing telaprevir were included in the study and followed for up to 12 months after the index hepatitis C claim. "

01/01/2015 - "We evaluated the clinical value of baseline FibroScan values for the prediction of safety and efficacy of telaprevir-based therapy in patients with advanced fibrosis and cirrhosis in the telaprevir Early Access Program HEP3002. "
12/01/2015 - "HPC3005 is a multicentre, open-label, telaprevir trial in HCV/HIV coinfected patients with severe fibrosis or compensated cirrhosis. "
09/30/2013 - "The 16-week interim report of the HEP3002 trial expanded the access program to Telaprevir, enrolling patients with advanced fibrosis who fulfilled the safety criteria of registration trials only, and offered an unbiased evaluation of Telaprevir tolerability and safety in this most in-need population, since the rates of treatment discontinuation due to adverse events were up to 14%. "
09/01/2015 - "We report a 53-year-old patient with cirrhosis due to HCV who started the classic treatment associated with telaprevir. "
04/01/2015 - "SVR rates were 46% (95% CI: 42-50) and 60% (95% CI: 57-64) in telaprevir patients with and without cirrhosis, respectively. "

02/01/2012 - "In telaprevir trials, approximately half of treated patients had rash. "
10/01/2015 - "After 5 days of treatment, he suffered from a telaprevir-associated skin rash on his body and four limbs. "
05/01/2015 - "Similar Success Rates but Lower Incidence of Telaprevir-Related Rash in HIV/HCV Coinfected as Compared to HCV-Monoinfected Patients Treated With Triple Anti-HCV Therapy."
12/01/2013 - "Patients treated with telaprevir may have a more severe course and more frequently require discontinuation of their antiviral therapy due to extensive rash or laboratory abnormalities. "
03/01/2013 - "High Incidence of Telaprevir-associated Severe Rash Leading to Discontinuation."